Glaukos (NYSE:GKOS) Given New $234.00 Price Target at BTIG Research

Glaukos (NYSE:GKOS) had its price target increased by BTIG Research from $205.00 to $234.00 in a report released on Thursday, Benzinga reports. The firm presently has a “buy” rating on the medical instruments supplier’s stock. BTIG Research‘s price target would suggest a potential upside of 28.95% from the stock’s current price.

Several other brokerages have also weighed in on GKOS. Citigroup raised their target price on Glaukos from $175.00 to $188.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Mizuho set a $225.00 price target on shares of Glaukos in a research report on Thursday. Stifel Nicolaus raised their price objective on shares of Glaukos from $175.00 to $190.00 and gave the stock a “buy” rating in a research report on Thursday, July 30th. Truist Financial set a $255.00 price objective on shares of Glaukos in a research note on Thursday. Finally, Jefferies Financial Group increased their price target on shares of Glaukos from $190.00 to $210.00 and gave the stock a “buy” rating in a report on Tuesday, September 22nd. Thirteen analysts have rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average target price of $194.93.

Glaukos Stock Up 0.2%

Shares of Glaukos stock opened at $181.47 on Thursday. The firm has a market cap of $10.70 billion, a price-to-earnings ratio of -55.84 and a beta of 0.69. The company has a debt-to-equity ratio of 0.10, a current ratio of 5.04 and a quick ratio of 4.46. Glaukos has a 1 year low of $76.88 and a 1 year high of $191.62. The company has a 50-day moving average of $171.24 and a 200 day moving average of $139.87.

Glaukos (NYSE:GKOS) last issued its earnings results on Wednesday, October 28th. The medical instruments supplier reported $0.47 earnings per share for the quarter, beating analysts’ consensus estimates of ($0.10) by $0.57. The business had revenue of $211.03 million during the quarter, compared to analyst estimates of $168.04 million. Glaukos had a negative return on equity of 6.37% and a negative net margin of 30.68%. Glaukos’s revenue was up 58.0% on a year-over-year basis. During the same period in the previous year, the company posted ($0.16) EPS. As a group, sell-side analysts anticipate that Glaukos will post -0.32 earnings per share for the current fiscal year.

Insiders Place Their Bets

In other news, COO Joseph E. Gilliam sold 60,000 shares of the business’s stock in a transaction on Tuesday, August 11th. The shares were sold at an average price of $179.74, for a total transaction of $10,784,400.00. Following the completion of the sale, the chief operating officer directly owned 72,588 shares of the company’s stock, valued at $13,046,967.12. The trade was a 45.25% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. Also, Director Gilbert Kliman sold 2,500 shares of Glaukos stock in a transaction dated Wednesday, August 19th. The shares were sold at an average price of $190.00, for a total value of $475,000.00. Following the completion of the transaction, the director directly owned 37,406 shares in the company, valued at $7,107,140. This represents a 6.26% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. Insiders sold 83,025 shares of company stock worth $14,950,006 in the last three months. Company insiders own 5.90% of the company’s stock.

Institutional Inflows and Outflows

A number of institutional investors and hedge funds have recently added to or reduced their stakes in the stock. Allworth Financial LP acquired a new stake in Glaukos in the 2nd quarter worth approximately $28,000. CoreCap Advisors LLC bought a new stake in Glaukos during the 3rd quarter worth about $33,000. Fortitude Family Office LLC acquired a new position in shares of Glaukos during the third quarter valued at $36,000. IFP Advisors Inc boosted its position in shares of Glaukos by 523.4% in the 2nd quarter. IFP Advisors Inc now owns 293 shares of the medical instruments supplier’s stock worth $41,000 after purchasing an additional 246 shares during the last quarter. Finally, Parallel Advisors LLC grew its position in shares of Glaukos by 159.2% during the 1st quarter. Parallel Advisors LLC now owns 368 shares of the medical instruments supplier’s stock worth $40,000 after buying an additional 226 shares during the period. 99.04% of the stock is owned by hedge funds and other institutional investors.

Glaukos News Roundup

Here are the key news stories impacting Glaukos this week:

• Positive Sentiment: Record revenue beat expectations: Third-quarter revenue increased approximately 58% year over year to $211.0 million, exceeding the $168.0 million consensus estimate. Gross profit rose to $179.9 million. Glaukos Corporation Reports Third-Quarter Earnings
• Positive Sentiment: Profitability materially outperformed forecasts: Glaukos reported adjusted earnings of $0.47 per share, compared with analysts’ expected loss of approximately $0.10–$0.12 per share and a year-ago loss of $0.16. GAAP net income attributable to common shareholders was $2.0 million, or $0.03 per diluted share, marking a return to profitability. Glaukos Q3 Earnings and Revenue Results
• Positive Sentiment: Full-year guidance was sharply increased: Management raised 2026 net-sales guidance to $775 million–$785 million from $680 million–$700 million. It also introduced a preliminary 2027 sales target of approximately $1 billion, signaling confidence in sustained demand and product adoption. Glaukos Raises Sales Outlook
• Positive Sentiment: Cash generation remained solid: Operating activities generated $14.8 million, while Glaukos ended the quarter with $162.3 million in cash and cash equivalents and modest capital spending of $2.7 million.
• Neutral Sentiment: Investor expectations are elevated: The stock is near its 52-week high, while the reported P/E remains negative and the company continues to post negative trailing profitability metrics. Continued execution will be necessary to support the higher valuation.
• Negative Sentiment: Insider selling is a potential overhang: Company insiders reported 32 open-market sales and no purchases during the past six months. In addition, the median analyst price target cited in the provided reports was $165, below the current share-price range.

About Glaukos

Glaukos Corporation is an ophthalmic medical-technology company focused on developing and commercializing therapies for chronic eye diseases. The company’s principal areas of focus include glaucoma, corneal disorders and retinal diseases, with an emphasis on treatments that may reduce reliance on conventional pharmaceuticals or more invasive surgical procedures.

Glaukos is best known for its micro-invasive glaucoma surgery (MIGS) products, including the iStent family of implantable devices used to help lower intraocular pressure in patients with glaucoma.